On 18 September 65, Dr. Opas Karn Kawinpong Director-General of the Department of Disease Control said that the fact that Thailand has provided ready-made immunity or Long Acting Antibody (LAAB) to the people who are in need is considered to raise the level of strengthening immunity against COVID-19 to take care of and protect the health of the people. especially for patients with low immunity The body is unable to build immunity by vaccination. 608 risk groups, such as chronic renal failure patients undergoing dialysis. Organ or bone marrow transplanters receiving immunosuppressant medications immune compromised This group, if infected, may be at risk of severe illness or high chance of death. The Immunologic Function, or LAAB, will help boost immunity in people who are less responsive to vaccines than the general population. Once injected, the body will create a high immunity to the virus immediately after injection. make a lot of benefits To reduce the risk of death in such patients. In foreign countries, LAAB has been registered to use immunosuppressants in LAAB in the treatment of vulnerable covid patients at risk of death, such as the United States, Japan.
In Thailand, LAAB immunosuppressants are imported and first injected into chronic renal failure patients undergoing dialysis. at Bamrasnaradura Institute on July 27, 2022 and sent to various provinces Nationwide since August 1, 2022, target groups in the early stages of chronic renal failure patients who need kidney replacement therapy (dialysis) who have received organ transplants. bone marrow transplant patients They can consult a doctor to be considered in enhancing their immunity against COVID with LAAB, or they can contact the hospital for injections. At the same time, the Ministry of Public Health The policy has been given to all provincial public health offices. Survey the number of eligible patients in all hospitals under in order for the target group to be thoroughly immune from LAAB. In addition, the Ministry of Public Health It is considering adding target groups that need immunization, such as cancer patients undergoing chemotherapy and radiation therapy, organ transplant patients who need high-dose immunosuppressants, and people with cancer. Items to be treated with immunosuppressants and other immunocompromised patients
Dr. Opas added that In early September 2022, a COVID-19 patient aged 105 years and never vaccinated for COVID-19 was admitted to a hospital on September 3, 2022 with high fever, sputum, oxygen. low blood and later had a bacterial lung infection. This patient received antiretroviral therapy on the first day. But due to old age, the risk of death Doctors therefore consider giving patients ready-made immunotherapy (LAAB) on September 4, 2022, along with antibiotics. which since September 10, 2022, the patient’s symptoms gradually better in order The symptoms of lung infection decreased, fever decreased, blood oxygen returned to normal. and patients can go home on September 14, 2022, the total duration of treatment is less than 2 weeks. Immunotherapy or LAAB is likely to be effective in treating elderly patients in the at-risk group with no immunity. However, the Ministry of Public Health also emphasizes Reiterating that all elderly people are advised to get vaccinated against COVID as soon as possible before they become infected.
In this regard, self-protection against COVID-19 can be carried out in accordance with the highest prevention measures for COVID-19, 2U, namely Universal Prevention, frequent hand washing, social distancing, wearing masks, the elderly, patients with 7 chronic diseases, and pregnant women avoid going to places. Crowded and Universal Vaccination is the vaccination of COVID-19, especially the 608 group of other patients and their close caregivers. should get a booster needle When receiving the last dose at least 4 months or more because the immunity will decrease over time. If infected, can become seriously ill. For more information, contact the Department of Disease Control hotline, call 1422.